Bilirubin in the premature: toxic waste or natural defense?
During the first days of life when antioxidant defenses are reduced, serum bilirubin is increased physiologically. Because bile pigments protect easily oxidizable substances from destruction (2), it has been suggested that bilirubin functions as an antioxidant in term neonates (3). Nevertheless, neonatal hyperbilirubinemia is still widely regarded as clinically problematic, and bilirubin is regarded as a toxic metabolic waste. However, the physiologic early neonatal increase in serum bilirubin may provide a protective antioxidant defense mechanism to compensate for otherwise deficient antioxidant enzymes, especially in premature neonates with increased susceptibility to OFR-mediated diseases. We tested this possibility by examining the relationship between serum bilirubin concentration and antioxidant activity in the blood of premature infants.
We studied 41 premature neonates (<36 weeks gestational age) born consecutively from September 1996 to March 1997 at the Shaare Zedek Medical Center during their first week of life. All infants with indwelling arterial catheters were potential candidates for study. Blood samples (50 [micro]L) were taken for measurement of total antioxidant status concurrently with the clinical bilirubin samples. Samples were taken beginning on day 2 of life and every other day for as long as an indwelling catheter was in place. Infants with Coombs-positive hemolytic anemia and/or glucose-6-phosphate dehydrogenase deficiency were excluded. Serum total bilirubin was measured by reflectance spectrophotometry (Kodak Ektachem). The study was approved by the Institutional Review Board.
We measured the peroxyl radical-trapping capability (Randox Laboratories) of human blood as an indicator of total antioxidant activity (TAA) (4). This method, based on the method of Miller et al. (5), uses the peroxidase activity of metmyoglobin combined with its interaction with a phenothiazine compound to form a radical cation intermediate as a measure of antioxidant status. The method derives from the observation that when 2,2'azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) is incubated with a peroxidase (such as metmyoglobin) and hydrogen peroxide, the relatively long-lived radical cation, [ABTSx.sup.+] is produced. In the presence of antioxidant reductants and hydrogen donors in plasma, the absorbance of this radical cation is quenched to an extent related to the antioxidant capacity of the fluid. The system is calibrated with a 2.5 mmol/L solution of Trolox (an [alpha]-tocopherol analog with good water solubility). Results correlate with the sum of the individual radical-trapping capabilities of the major antioxidants in plasma.
Mean values [+ or -] SD were calculated for continuous variables and compared by the Student t-test. Correlations between clinical variables were analyzed using a Pearson correlation. Combined analysis was performed using a best subset regression model, followed by a Spearman correlation to define correlations between variables.
The mean birth weight of the infants was 1374 [+ or -] 659 g, and the mean gestational age was 30.4 [+ or -] 3.6 weeks. The mean Apgar scores were 8 [+ or -] 2 and 8 [+ or -] 1 at 1 and 5 min, respectively. A total of 85 samples were taken, with 11 of the infants having three or more serial samples taken.
Serum bilirubin was significantly correlated (P = 0.005) with total antioxidant status (Fig. 1). Other than through its effect on bilirubin concentrations, treatment with phototherapy had no independent effect on TAA (P = 0.24).
Gestational age did not affect TAA (P = 0.91; only the initial TAA value was considered for those infants with several measurements). Birth weight (P = 0.79), the sex of an infant, and the concentration of inspired oxygen (P = 0.12) were not significantly correlated with TAA.
Mean total antioxidant status values were related to postnatal day of life (DOL), with an initial increase from day 2 to 4, followed by a decrease during the remainder of the first week of life (Table 1).
Best subset regression of the entire data sample, with TAA as the dependent variable and an F-to-remove of 3.9, confirmed that TAA can be predicted from a linear combination of the bilirubin at time of sampling and the DOL studied and that both bilirubin and DOL have independent effects on TAA. Variables tested and found not to add to the predictability of TAA included birth weight, gestational age, sex, use of phototherapy, and Fi[O.sub.2]. Spearman correlation revealed no correlation between the variables bilirubin and DOL.
Our present findings extend previous reports (3). Stocker et al. (6) showed that bilirubin at physiologic concentrations can protect linoleic acid from oxidation in vitro. Farrera et al. (7) compared the peroxyl antioxidant trapping potential of various substances and found that free bile pigments showed higher activity than did the vitamin E analog Trolox. According to Frei et al. (8), bilirubin contributes ~10% of the total antioxidant status. Serum antioxidant potential in prematures increases over the first 4 days of life, as does serum bilirubin. However, a direct correlation between serum bilirubin and antioxidant potential has not been shown previously in prematures (9).
[FIGURE 1 OMITTED]
Animal studies support a protective effect of hyperbilirubinemia. Dennery et al. (10) exposed Gunn rats to hyperoxia and demonstrated that jaundiced rats had less oxidative damage, as evidenced by the lower concentrations of lipid peroxides, conjugated dimes, and carbonyl proteins in jaundiced rats than in nonjaundiced rats.
In term human infants, Belanger et al. (11) detected a decrease in antioxidant capacity after exchange transfusion, implying a correlation between bilirubin removal and antioxidant capacity. Gopinathan et al. (1) observed a direct correlation between serum bilirubin and total antioxidant potential at birth in term infants, which they did not find in prematures. However, as a result of aggressive phototherapy in these premature infants, their bilirubin at 5 days reached only a mean of 67 [+ or -] 47 mmol/L (3.9 [+ or -] 2.8 mg/dL). Thus, there was not a wide enough range of bilirubin values to demonstrate any correlation, even should one exist.
Benaron et al. (12) and Hegyi et al. (13) noted lower serum bilirubin concentrations in neonates with oxygen radical-mediated diseases as compared with control, age-matched infants. These data imply that bilirubin may be consumed in response to the generation of oxygen-derived free radicals, supporting an active clinical role for bilirubin as an antioxidant. Conversely, a retrospective study of early bilirubin concentrations in relation to the subsequent development of retinopathy of prematurity in prematures (4,14) did not demonstrate any such correlation. However, all clinical studies of this type are hampered by the fact that clinical disease is multifactorial and that the relationship with bilirubin, if one exists, may well be more complex than a direct correlation. Oxidative stress may consume available antioxidant resources (10) as suggested above, or conversely, it may induce antioxidant release (15) or some combination thereof. We have, therefore, correlated serum bilirubin not with clinical disease, but rather with a biochemical index of antioxidant status, demonstrating that bilirubin does contribute to the total antioxidant potential of the premature neonate.
We recognize that the fact that some of our babies were sampled more than once whereas others only were sampled once represents a possible limitation to our study. As such, these data do not purport to represent the general antioxidant status of premature infants. Nevertheless, they do demonstrate a positive relationship between serum bilirubin and antioxidant status.
Bilirubin management in the term neonate is currently in a state of flux (16-22). Therapeutic recommendations that have been accepted for years are being reevaluated and liberalized. Our observations, if further validated, suggest that the time may have arrived to also reevaluate clinical bilirubin management of the preterm infant. However, these relationships are complex and multifaceted. Thus, any consideration of potential clinical applications of this information may be undertaken only with extreme caution and with additional supportive data.
This study was supported by grant no. 3302 from the Chief Scientist Office of the Ministry of Health of Israel, the Gamburg Neonatal Research Fund, and the generous contributions of Mr. and Mrs. Stephen Hammerman.
(1.) Gopinathan V, Miller NJ, Milner AD, Rice Evans CA. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett 1994;349:197-200.
(2.) Bernhard K, Ritzel G, Steiner KU. Uber eine biologische bedeutung der gallenfarbstorre: bilirubin and biliverdin als antioxydantien fur das vitamin A and die essentiellen fettsauren. Helv Chim Acta 1954;37:306-13.
(3.) McDonagh A. Is bilirubin good for you? Clin Perinatol 1990;17:359-69.
(4.) Wagner DDM, Burton GW, Ingold KV, Barclay LRC, Locke ST. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 1987;924:408-19.
(5.) Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, MiInerA. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-12.
(6.) Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235:1043-6.
(7.) Farrera JA, Jauma A, Ribo JM, Peire MA, Parellada PP, Rogues Choua S, et al. The antioxidant role of bile pigments evaluated by chemical tests. Bioorg Med Chem 1994;2:181-5.
(8.) Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A 1988;85:9748-52.
(9.) Hidalgo FJ, Zamora R, Dillard CJ, Tappel AL. Can serum bilirubin be an index of in vivo oxidative stress? Med Hypotheses 1990;33:207-11.
(10.) Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 1995;19:395-404.
(11.) Belanger S, Lavoie JC, Chessex P. Influence of bilirubin on the antioxidant capacity of plasma in newborn infants. Biol Neonate 1997;71:233-8.
(12.) Benaron DA, Brwen FW. Variation of initial serum bilirubin rise in newborn infants with type of illness. Lancet 1991;338:78-81.
(13.) Hegyi T, Goldie E, Hiatt M. The protective role of bilirubin in oxygen radical diseases of the preterm infant. J Perinatol 1994;14:296-300.
(14.) Gaton DD, Gold J, Axer Siegel R, Wielunsky E, Naor N, Nissenkorn I. Evaluation of bilirubin as a possible protective factor in the prevention of retinopathy of prematurity. Br J Ophthalmol 1991;75:532-4.
(15.) Romeo MG, Tina LG, Scuderi A, Di Pietro M, Caracciolo M, Distefano G. Variations of blood bilirubin levels in the newborn with and without retinopathy of prematurity (ROP). Pediatr Med Chir 1994;16:59-62.
(16.) Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992;89:809-18.
(17.) Gartner LM, Herrarias CT, Sebring RH. Practice patterns in neonatal hyperbilirubinemia. Pediatrics 1998;101:25-31.
(18.) Wennberg RP. Bilirubin recommendations present problems: new guidelines simplistic and untested. Pediatrics 1992;89:821-2.
(19.) Poland RL. In search of a gold standard for bilirubin toxicity. Pediatrics 1992;89:823-4.
(20.) Cashore WJ. Hyperbilirubinemia: should we adopt a new standard of care? Pediatrics 1992;89:824-6.
(21.) Brown AK, Seidman DS, Stevenson DK. Jaundice in healthy, term neonates: do we need new action levels or new approaches? Pediatrics 1992;89: 827-9.
(22.) Johnson L. Yet another expert opinion on bilirubin toxicity! Pediatrics 1992;89:829-30.
Cathy Hammerman,  * Robert Goldstein,  Michael Kaplan, [1,3] Maya Eran,  Doris Goldschmidt,  Arthur I. Eidelman, [1,3] and Lawrence M. Gartner  ( Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel 91031;  Gastroenterology Metabolism Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel 91031;  Hebrew University, Hadassah School of Medicine, Jerusalem, Israel 91031;  Department of Pediatrics, University of Chicago, Chicago, IL 60637; * address correspondence to this author at: Department of Neonatology, P.O. Box 3235, Shaare Zedek Medical Center, Jerusalem, Israe1 91031; fax 972-02-652-0689, e-mail email@example.com)
Table 1. TAA and bilirubin vs day of life. Day of life Bilirubin TAA 2 (n=22) 6.1 [+ or -] 1.7 1.34 [+ or -] 0.34 4 (n=22) 7.4 [+ or -] 3.6 1.41 [+ or -] 0.31 6 (n=22) 5.9 [+ or -] 3.2 1.14 [+ or -] 0.36 (a) 8 (n=12) 6.3 [+ or -] 1.7 1.07 [+ or -] 0.37 (a) a P <0.05 compared with day 4 of life.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||Hammerman, Cathy; Goldstein, Robert; Kaplan, Michael; Eran, Maya; Goldschmidt, Doris; Eidelman, Arth|
|Date:||Dec 1, 1998|
|Previous Article:||Furosemide interference in newer free thyroxine assays.|
|Next Article:||Mechanism of interference by hemolysis in immunoassays and requirements for sample quality.|